Armata Pharmaceuticals, Inc. ARMP
3.09 USD +0.24 (+8.42%)
At closeNov 3, 2026, 4:00 PM EST
3.09 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
2.89 Day range 3.10
2.75 52-week range 14.98
- YTD
- -50.80%
- 1 year
- -36.02%
- Market cap
- 114.89M
- Revenue (ttm)
- 3.72M
- EPS (ttm)
- -5.29
- Shares out
- 36.18M
- Forward P/E
- -1.30
- YTD return
- -50.80%
- 1-year return
- -36.02%
- Volume
- 42.92K
- Avg volume
- 191.05K
- Open
- 2.89
- Previous close
- 2.85
- Day's range
- 2.89 – 3.10
- 52-week range
- 2.75 – 14.98
- Beta
- 0.81
- Analysts
- Buy
- Price target
- 7.00 (+126.5%)
1Y -1.86 (-38.43%)
Key statistics
- Enterprise value
- 216.71M
- PEG ratio
- 0.00
- Price / sales
- 19.85
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -31.06M
- Total cash
- 26.41M
- Total debt
- 146.14M
- Return on equity
- 0.00%
- Short % of float
- 0.04%
- 50-day average
- 2.26
- 200-day average
- 2.65
Analyst view
Consensus: buy
Buy
Price target (mean) 7.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.35.
Financials — quick view
ARMP Revenue — quarterly 0
ARMP Net income — quarterly 74.14M
ARMP EPS — quarterly 2.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.28 | -0.15 | +0.13 | +46.43% |
| Aug 13, 2024 | Jun 1, 2024 | -0.52 | -0.65 | -0.13 | -25.00% |
| May 7, 2024 | Mar 1, 2024 | -0.28 | -0.69 | -0.41 | -146.43% |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -0.55 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.33 | -0.31 | +0.02 | +6.06% |
| Aug 14, 2023 | Jun 1, 2023 | -0.35 | -0.28 | +0.07 | +20.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- armatapharma.com
News
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program 
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program 
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target 
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development 
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on ARMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIRX DEBORAH L. | Chief Executive Officer | Stock Award(Grant) | Mar 13, 2024 | 260,000 |
| RYCHLIK RICHARD | Officer | Stock Award(Grant) | Mar 13, 2024 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bank of America Corporation | 1.75% | 634,047 | 1.29M | Sep 29, 2024 |
| Vanguard Group Inc | 0.62% | 225,287 | 459.61K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.30% | 107,066 | 218.43K | Sep 29, 2024 |
| Edgewood Management Llc | 0.28% | 100,000 | 204.01K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.21% | 75,382 | 153.79K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.13% | 46,496 | 94.86K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.32% | 115,302 | 235.23K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.29% | 106,021 | 216.29K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.18% | 66,382 | 135.43K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.16% | 59,680 | 121.75K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.06% | 21,354 | 43.56K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 17,469 | 35.64K | Oct 30, 2024 |